Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Rubbia-Brandt L, Giostra E, Quadri R, Mal P, Mentha G, Sparhr J, Zarski J, Borisch B, Hadengue A & Negro F (1999) Evidence that liver steatosis is virally-mediated in a subset of patients infected by hepatitis C virus (HCV) genotype 3
Key findings from this phase 2 obesity trial included: Mean weight reduction of up to approximately 24.2% at the highest dose (12 mg) after 48 weeks Dose-dependent reductions in body weight across all active treatment arms Significant reductions in waist circumference, blood pressure, and lipid parameters Improvements in fasting glucose and insulin resistance markers A separate phase 2 trial in adults with type 2 diabetes (published in 2023) demonstrated meaningful HbA1c reductions alongside substantial weight loss, suggesting potential dual utility in both obesity and glycaemic management
GLP-1 (7-37) is a truncated, bioactive form of GLP-1 that is the product of proglucagon processing in intestinal endocrine L cells
Average reduction in body weight over 6 months* Users say this is more effective than anything theve ever tried Average reduction in waist size Users have achieved lasting weight loss I seriously don't know what I would have done without Tirzepitide
US$ 26.20
US$ 21.89
US$ 27.98
US$ 28.20
US$ 29.86
US$ 20.20
US$ 26.39
